FDA approves novel treatment for major depressive disorder; vote taken on stem cell therapy for ALS; preservation-free Iyuzeh now available; CDC recommends RSV vaccine for during pregnancy; investigational treatment shows promise in familial chylomicronemia syndrome.
Sotatercept is an investigational activin signaling inhibitor.
Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.
In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.
Patient deemed ineligible for a transplant with human heart owing to peripheral vascular disease, complications with internal bleeding.
Roughly 75% of Maricopa County’s confirmed heat deaths were at bus stops, in yards, driveways, parking lots, and parks.
Associations seen for all individual substances; association strongest for amphetamine/methamphetamine.
Empagliflozin is a sodium-glucose co-transporter 2 inhibitor.
Screening with blood pressure measurements has substantial net benefits and is recommended throughout pregnancy.
Changes in office systolic BP of −14.1, −13.2, −6.9, and −4.1 mm Hg seen with 100, 50, 12.5mg once daily of lorundrostat and placebo.
Incident hypertension, statin use higher with tenofovir alafenamide fumarate compared with tenofovir disoproxil fumarate.
A regulatory decision is expected by October 8,2023.
Seasonal variation of 1.4 mm Hg tied to nearly 5% variation in blood pressure control.
Individual patient data meta-analysis shows increased risk for dementia for those with untreated hypertension.
NSAID use positively linked to VTE, with extra VTE events in those with concomitant high-, medium-risk contraception use.
Higher intake of celluloses (E460 to E468) positively associated with higher risks for CVD and coronary heart disease.
Combination approach better than statin monotherapy for all-cause mortality at 1, 3, and 5 years in acute coronary syndromes.
Significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin in network meta-analysis
Janssen noted that the phase 3 UNISUS study will continue as planned.
Variation in coverage seen by program, drug, and cardiovascular disease condition
